Workshop 1 – Technology & Entrepreneurship
Date: 24 July (Friday) 10:40 – 12:10 (GMT+8)
Venue: www.bioasiataiwan.com - Online event platform
Dr. Artzi is an Assistant Professor at the Department of Medicine, Division of Engineering in Medicine, Brigham and Women’s Hospital, Harvard medical School.
She is a Principal Research Scientist at MIT and an Associate Member of the Broad Institute of Harvard and MIT. She completed her postdoctoral studies at the laboratory of Prof. Elazer Edelman at MIT focusing on studying tissue:biomaterial interactions and designing smart biomaterials for theranostic applications.
Dr. Artzi is the recipient of multiple grants and awards, including the One Brave Idea award, The Stepping Strong Innovator Award, Nano-Micro-Letters Researcher Award, and the Controlled Release Society Young Investigator Award.
Currently, Dr. Artzi directs multiple research venues aiming to integrate science, engineering and medicine to rationally design personalized materials to improve human health, and has co-founded a startup company, BioDevek, which develops the next-generation adhesive materials for the prevention of leakage and its associated complications following internal surgeries.
Speech title & Synopsis
There are almost 100M surgically-initiated wounds annually worldwide. Up to 30% of these patients suffer from leakage from the suture line, leading to additional procedures and prolonged hospitalization, that are associated with high morbidity and mortality. The application of an adhesive material that can seal the suture line to provide with optimal adhesion and mechanical properties would save a lot of lives and reduce treatment costs. However, the generic use of ‘inert’ materials for a range of applications does not consider tissue type and state, results in suboptimal performance and unpredictable clinical outcomes. A spinoff company, BioDevk, I co-founded together with Prof. Elazer Edelman from MIT, is working on the development of the next-generation adhesive materials that can seal the suture line following internal surgeries. These materials are designed to sense their environment and thrive differentially based on the tissue microenvironment it is applied to, and provide with appropriate mechanical properties and adhesion. These materials are biocompatible and degradable, unlike most of the commercially-available materials that force physicians to choose between adequate adhesion and biocompatibility. This platform has been tested in small and large animal models and has shown excellent sealing properties following vascular surgeries. Also, the ability of the material to be applied locally can be leveraged to release a range of therapeutics, overcoming the need to cross multiple biological barriers following their systemic administration. We have demonstrated that such materials can, in combination with embedded nanoparticles, provide efficacious delivery of combination therapy with programmed release profiles, to enhance the therapeutic window, in multiple cancer models and in tissue engineering. The translation of such adaptive materials will provide the scientific, pharmaceutical and clinical communities with unprecedented opportunities for the development of new clinically-relevant localized therapies that can enhance efficacy and minimize systemic toxicity.